Editor’s note: This is an automatically generated transcript. Please notify [email protected] if there are concerns regarding accuracy of the transcription The kidneys, in addition to removing toxins, ...
Csaba P. Kovesdy, MD, FASN This article is the first in a series that will discuss various aspects of hyperphosphatemia in patients with renal disease. Csaba P. Kovesdy, MD, chief of nephrology at the ...
Credit: Ardelyx. Xphozah is expected to be available in November 2023. The Food and Drug Administration (FDA) has approved Xphozah ® (tenapanor) to reduce serum phosphorus in adults with chronic ...
Credit: Ardelyx. Xphozah is a first-in-class oral medication designed to block sodium/hydrogen exchange 3 in the GI tract. Xphozah ® (tenapanor) is now available to reduce serum phosphorus in adults ...
“Finally!” Piper Sandler analysts cheered in a research note on Ardelyx Inc., which after spending three years battling the U.S. FDA, secured approval of Xphozah (tenapanor) for treating ...
LOS ALTOS, Calif., June 10, 2025 (GLOBE NEWSWIRE) -- Unicycive Therapeutics (UNCY), Inc. (Nasdaq: UNCY or the “Company”), a clinical-stage biotechnology company developing therapies for patients with ...
WALTHAM, Mass., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class ...
LOS ALTOS, Calif., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease (the ...
LOS ALTOS, Calif., Nov. 11, 2024 (GLOBE NEWSWIRE) -- Unicycive Therapeutics (UNCY), Inc. , a clinical-stage biotechnology company developing therapies for patients with kidney disease (the “Company” ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback